- Current report filing (8-K)

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

November 13, 2009

Date of Report (Date of earliest event reported)

 

 

NEUROGEN CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Delaware (State or other jurisdiction of incorporation)

0-18311 (Commission File Number)

22-2845714 (I.R.S. Employer Identification No.)

 

 

45 Northeast Industrial Road

Branford, Connecticut   06405

(Address of principal executive offices) (Zip Code)

 

[phone]

(Registrant's telephone number, including area code)

 

None

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

 

 

 

---

 

Item 5.02(b) Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On November 13, 2009, Kenneth Sprenger’s employment as Senior Vice President, Clinical Development and Operations of Neurogen Corporation was terminated without cause.  Under Dr. Sprenger’s employment agreement, dated as of March 27, 2009, he was entitled to receive, and the Company has paid to him, a severance payment of $375,000 equal to twelve months of his base salary and target bonus.

SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROGEN CORPORATION
	(Registrant)
	By: /s/ THOMAS A. PITLER
	Name: Thomas A. Pitler
Date: November 18, 2009	Title: Senior Vice President and Chief Business and Financial Officer